Total Payments
$4,753
2024 Payments
$589.14
Companies
38
Transactions
237
Medicare Patients
2,248
Medicare Billing
$360,191
Payment Breakdown by Category
Food & Beverage$4,753 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,753 | 237 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $713.87 | 29 | $0 (2024) |
| Novo Nordisk Inc | $711.48 | 39 | $0 (2024) |
| ABBVIE INC. | $669.83 | 43 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $319.82 | 16 | $0 (2024) |
| Amgen Inc. | $252.30 | 13 | $0 (2024) |
| Corcept Therapeutics | $211.65 | 9 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $157.58 | 9 | $0 (2022) |
| Antares Pharma, Inc. | $123.98 | 6 | $0 (2023) |
| Insulet Corporation | $122.06 | 4 | $0 (2021) |
| Radius Health, Inc. | $112.86 | 5 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $589.14 | 28 | Lilly USA, LLC ($113.43) |
| 2023 | $935.46 | 58 | Lilly USA, LLC ($199.51) |
| 2022 | $731.10 | 41 | Novo Nordisk Inc ($165.17) |
| 2021 | $213.13 | 11 | Clarus Therapeutics Inc. ($45.67) |
| 2020 | $444.56 | 23 | AbbVie Inc. ($71.81) |
| 2019 | $1,275 | 57 | Novo Nordisk Inc ($248.89) |
| 2018 | $565.29 | 19 | Lilly USA, LLC ($186.52) |
All Payment Transactions
237 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Food and Beverage | In-kind items and services | $21.08 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 11/26/2024 | Amneal Pharmaceuticals LLC | UNITHROID (Drug) | Food and Beverage | In-kind items and services | $20.92 | General |
| Category: ENDOCRINOLOGY | ||||||
| 10/22/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $20.05 | General |
| Category: Diabetes | ||||||
| 10/08/2024 | ABBVIE INC. | SYNTHROID (Drug) | Food and Beverage | In-kind items and services | $15.02 | General |
| Category: IMMUNOLOGY | ||||||
| 09/23/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $21.34 | General |
| Category: Inflammation/Rare Disease | ||||||
| 09/18/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Food and Beverage | In-kind items and services | $16.08 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 09/17/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $34.82 | General |
| Category: Diabetes | ||||||
| 09/10/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $20.51 | General |
| 08/20/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Food and Beverage | In-kind items and services | $22.58 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 08/15/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $22.67 | General |
| Category: Diabetes Care | ||||||
| 07/31/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $28.42 | General |
| Category: Endocrinology | ||||||
| 07/29/2024 | ABBVIE INC. | SYNTHROID (Drug) | Food and Beverage | In-kind items and services | $17.06 | General |
| Category: IMMUNOLOGY | ||||||
| 07/16/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $18.38 | General |
| Category: Cardiology | ||||||
| 07/12/2024 | BETA BIONICS, INC. | iLet Bionic Pancreas (Device), iLet Bionic Pancreas, iLet Bionic Pancreas | Food and Beverage | In-kind items and services | $16.74 | General |
| Category: Automated insulin delivery system | ||||||
| 07/09/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $18.15 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 06/04/2024 | IBSA Pharma Inc. | Tirosint (Drug), Licart | Food and Beverage | Cash or cash equivalent | $23.82 | General |
| Category: Endocrinology | ||||||
| 05/28/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $16.86 | General |
| 05/16/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $31.76 | General |
| Category: Diabetes | ||||||
| 05/07/2024 | ABBVIE INC. | SYNTHROID (Drug) | Food and Beverage | In-kind items and services | $18.00 | General |
| Category: IMMUNOLOGY | ||||||
| 04/30/2024 | Amneal Pharmaceuticals LLC | UNITHROID (Drug) | Food and Beverage | In-kind items and services | $17.82 | General |
| Category: ENDOCRINOLOGY | ||||||
| 04/09/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $31.19 | General |
| Category: Endocrinology | ||||||
| 04/02/2024 | CeQur Corporation | CeQur Simplicity (Device) | Food and Beverage | Cash or cash equivalent | $20.00 | General |
| Category: Diabetes | ||||||
| 03/25/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $26.80 | General |
| Category: Diabetes | ||||||
| 03/19/2024 | Medtronic, Inc. | MINIMED 780G (Device) | Food and Beverage | In-kind items and services | $26.09 | General |
| Category: Durable Pump | ||||||
| 03/12/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $15.61 | General |
| Category: Endocrinology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 642 | 4,362 | $462,553 | $115,659 |
| 2022 | 8 | 566 | 2,863 | $353,491 | $88,805 |
| 2021 | 9 | 444 | 2,399 | $260,202 | $68,777 |
| 2020 | 12 | 596 | 3,406 | $227,012 | $86,949 |
Total Patients
2,248
Total Services
13,030
Medicare Billing
$360,191
Procedure Codes
36
All Medicare Procedures & Services
36 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 40 | 3,540 | $247,800 | $65,037 | 26.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 259 | 371 | $148,302 | $35,194 | 23.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 77 | 77 | $40,194 | $8,767 | 21.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 45 | 45 | $12,780 | $2,643 | 20.7% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 142 | 209 | $5,225 | $1,975 | 37.8% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 34 | 46 | $4,922 | $1,286 | 26.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 45 | 74 | $3,330 | $756.46 | 22.7% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 25 | 2,100 | $134,400 | $35,742 | 26.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 228 | 356 | $147,692 | $35,291 | 23.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 84 | 84 | $45,780 | $11,221 | 24.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 29 | 32 | $9,472 | $2,062 | 21.8% |
| 83036 | Hemoglobin a1c level | Office | 2022 | 125 | 188 | $4,700 | $1,793 | 38.2% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 36 | 55 | $6,215 | $1,538 | 24.7% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 12 | 12 | $3,540 | $756.00 | 21.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 27 | 36 | $1,692 | $401.42 | 23.7% |
| J0897 | Injection, denosumab, 1 mg | Office | 2021 | 24 | 1,860 | $112,260 | $31,062 | 27.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 188 | 262 | $107,237 | $26,968 | 25.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 36 | 36 | $19,656 | $5,261 | 26.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 24 | 25 | $7,117 | $1,683 | 23.7% |
| 83036 | Hemoglobin a1c level | Office | 2021 | 98 | 125 | $3,125 | $1,206 | 38.6% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Office | 2021 | 20 | 31 | $3,462 | $879.95 | 25.4% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 15 | 15 | $3,701 | $861.27 | 23.3% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Office | 2021 | 15 | 15 | $2,090 | $494.20 | 23.6% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 24 | 30 | $1,554 | $360.47 | 23.2% |
| J0897 | Injection, denosumab, 1 mg | Office | 2020 | 31 | 2,640 | $94,980 | $40,940 | 43.1% |
About Dr. Shristi Neupane, MD
Dr. Shristi Neupane, MD is a Internal Medicine healthcare provider based in Havre De Grace, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/11/2011. The National Provider Identifier (NPI) number assigned to this provider is 1699067520.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Shristi Neupane, MD has received a total of $4,753 in payments from pharmaceutical and medical device companies, with $589.14 received in 2024. These payments were reported across 237 transactions from 38 companies. The most common payment nature is "Food and Beverage" ($4,753).
As a Medicare-enrolled provider, Neupane has provided services to 2,248 Medicare beneficiaries, totaling 13,030 services with total Medicare billing of $360,191. Data is available for 4 years (2020–2023), covering 36 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Diabetes & Metabolism
- Location Havre De Grace, MD
- Active Since 05/11/2011
- Last Updated 07/05/2018
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1699067520
Products in Payments
- SYNTHROID (Drug) $365.09
- Ozempic (Drug) $359.87
- MOUNJARO (Drug) $254.73
- HUMULIN (Drug) $219.26
- Korlym (Drug) $211.65
- Androgel (Drug) $145.77
- FARXIGA (Drug) $144.06
- Synthroid (Drug) $140.52
- EVENITY (Biological) $127.19
- Omnipod (Device) $122.06
- TRULICITY (Drug) $111.82
- Rybelsus (Drug) $97.32
- NOCDURNA (Drug) $82.45
- BD Nano 2nd Gen Pen Needle (Device) $80.15
- SOLIQUA 100/33 (Drug) $78.34
- BAQSIMI (Drug) $75.32
- TOUJEO (Biological) $73.48
- SOLIQUA 100/33 (Biological) $73.48
- Eversense (Device) $73.00
- CeQur Simplicity (Device) $71.66
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Havre De Grace
Dr. Thomas Biondo, M.d, M.D
Internal Medicine — Payments: $14,095
Internal Medicine $14,095
Dr. Hi Sim, M.d, M.D
Internal Medicine — Payments: $13,591
Internal Medicine $13,591
Dr. Benjamin Lee, M.d, M.D
Internal Medicine — Payments: $1,720
Internal Medicine $1,720
Dr. Robert Rapp, Md, MD
Internal Medicine — Payments: $346.05
Internal Medicine $346.05
Dr. Suresh Dhanjani, M.d, M.D
Internal Medicine — Payments: $96.70
Internal Medicine $96.70
Dr. Matt Wachsman, Md Phd, MD PHD
Internal Medicine — Payments: $78.89
Internal Medicine $78.89